Please login to the form below

Not currently logged in
Email:
Password:

Vertex poaches new finance chief from Ironwood Pharmaceuticals

Boston-based biotech company appoints Tom Graney

Vertex Tom GraneyVertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer.

He will join the Boston-based biotech firm next week, when he will be responsible for the development and execution of Vertex’s financial strategy and operations.

Graney will report to Vertex’s chief operating office Ian Smith, who said: “As Vertex continues its evolution to a leading global biotech, it is critical that we continue to build a strong and experienced leadership team.

“Tom has the ideal blend of financial acumen, leadership skills, and industry experience that will be important as Vertex grows and expands as a global company."

Graney most recently spent three years at Ironwood Pharmaceuticals, overseeing its Finance, Corporate Strategy, Corporate Development, Quality, Supply Chain, IT, Corporate Communications and Investor Relations functions.

Prior to that he served at Johnson & Johnson for 20 years in the US and abroad, rising to worldwide VP of finance and CFO for its Ethicon Surgical Care business.

At Ironwood Pharmaceuticals Graney’s replacement as interim chief financial officer will be Gina Consylman, who currently serves as the Cambridge, Massachusetts firm’s VP of finance and chief accounting officer.

8th September 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics